Related Experiment Videos
[A case of CABG in a patient with chronic idiopathic thrombocytopenic purpura]
1Department of Cardiovascular Surgery, Mitsui Memorial Hospital, Tokyo, Japan.
Insights
High-dose gamma-globulin therapy effectively managed chronic idiopathic thrombocytopenic purpura (ITP) before open heart surgery. This treatment increased platelet counts, ensuring a safe and uneventful surgical procedure and recovery.
Area of Science:
- Cardiology
- Hematology
- Immunology
Background:
- Chronic idiopathic thrombocytopenic purpura (ITP) poses management challenges, especially in patients with coexisting ischemic heart disease requiring surgical intervention.
- Open-heart surgery in ITP patients necessitates careful management to prevent bleeding complications.
Observation:
- A patient with chronic ITP and ischemic heart disease underwent management for open-heart surgery.
- Preoperative treatment involved high-dose intravenous gamma-globulin therapy (400 mg/kg/day for five days).
Findings:
- The gamma-globulin therapy significantly increased the patient's platelet count from 5.8 x 10(4)/mm3 to 12.8 x 10(4)/mm3.
- Platelet transfusions were administered post-cardiopulmonary bypass and on the first postoperative day.
- Hemostasis was maintained throughout the procedure, and the postoperative course was uneventful.
Implications:
- High-dose intravenous gamma-globulin therapy is a preferred treatment option for managing ITP prior to open-heart surgery.
- This therapeutic approach can optimize platelet counts, mitigate surgical bleeding risks, and ensure favorable patient outcomes.
- The successful management highlights the potential of immunomodulatory therapies in complex surgical cases involving hematological disorders.
Abstract:
This is a report of the management of a patient with chronic idiopathic thrombocytopenic purpura (ITP) and ischemic heart disease. High-dose transvenous gamma-globulin therapy (400 mg/kg/day for five days) was started five days prior to operation, yielding an increase in platelet count from 5.8 X 10(4)/mm3 to 12.8 X 10(4)/mm3. Platelet transfusion was used at the end of cardiopulmonary bypass and on the first postoperative day. There were no problems with hemostasis during the operative procedure and the postoperative course was uneventful. We prefer high-dose transvenous gamma-globulin therapy for ITP prior to open heart surgery as a treatment of choice.